PUBLISHER: DelveInsight | PRODUCT CODE: 1159552
PUBLISHER: DelveInsight | PRODUCT CODE: 1159552
DelveInsight's , "Spasticity - Pipeline Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Spasticity Understanding
Spasticity: Overview
Spasticity is a condition in which there is an abnormal increase in muscle tone or muscle stiffness, which might interfere with movement and speech or be associated with discomfort or pain. Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may be related to spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Spasticity is generally caused by damage or disruption to the brain and spinal cord area responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place. Spasticity can harm growing children as it affects muscles and joints.
"Spasticity - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spasticity Emerging Drugs
HU-014 (Liztox) is a newly developed Botulinum toxin A. Botulinum toxin dose is measured in units (U) based on the median lethal dose (LD50) of the neurotoxin. HU-014 is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. The botulinum toxin weakens or paralyzes skeletal muscle by inhibiting neurotransmission between peripheral nerve endings and muscle fibers. The effects of botulinum toxin are transient; muscular function typically returns to baseline within a few months.
Myobloc (rimabotulinumtoxinB) injection is the first and only approved botulinum toxin Type B injectable indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults and the treatment of chronic sialorrhea in adults. MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic-nerved terminals. Currently it is being evaluated in Phase II/III clinical trials to treat upper and lower limb spasticity.
Further product details are provided in the report……..
Spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Spasticity drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Spasticity. The companies which have their Spasticity drug candidates in the most advanced stage, i.e. Phase III include, Huons.
DelveInsight's report covers around 20+ products under different phases of clinical development like
Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spasticity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Spasticity : Overview
Pipeline Therapeutics
Therapeutic Assessment
Spasticity - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
HU-014: Huons
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Myobloc: Supernus Pharmaceuticals
Drug profiles in the detailed report…..
Mid- Stage Products (Phase II)
LX-9211: Lexicon Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Lu AG06466: Lundbeck A/S
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Spasticity Key Companies
Spasticity Key Products
Spasticity -Unmet Needs
Spasticity -Market Drivers and Barriers
Spasticity -Future Perspectives and Conclusion
Spasticity Analyst Views
Spasticity Key Companies
Appendix